Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma
Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Codon Publications
2018-10-01
|
| Series: | Journal of Kidney Cancer and VHL |
| Subjects: | |
| Online Access: | https://jkcvhl.com/index.php/jkcvhl/article/view/109 |
| _version_ | 1818355501812940800 |
|---|---|
| author | Sharon Del Vecchio Robert J Ellis |
| author_facet | Sharon Del Vecchio Robert J Ellis |
| author_sort | Sharon Del Vecchio |
| collection | DOAJ |
| description | Cabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma. |
| first_indexed | 2024-12-13T19:42:20Z |
| format | Article |
| id | doaj.art-eb9baa695a524f0d86c1b80747c71a83 |
| institution | Directory Open Access Journal |
| issn | 2203-5826 |
| language | English |
| last_indexed | 2024-12-13T19:42:20Z |
| publishDate | 2018-10-01 |
| publisher | Codon Publications |
| record_format | Article |
| series | Journal of Kidney Cancer and VHL |
| spelling | doaj.art-eb9baa695a524f0d86c1b80747c71a832022-12-21T23:33:40ZengCodon PublicationsJournal of Kidney Cancer and VHL2203-58262018-10-015410.15586/jkcvhl.2018.109Cabozantinib for the Management of Metastatic Clear Cell Renal Cell CarcinomaSharon Del Vecchio0Robert J Ellis1Centre for Kidney Disease Research University of Queensland Princess Alexandra HospitalCentre for Kidney Disease Research University of Queensland Princess Alexandra HospitalCabozantinib is a multi-tyrosine kinase inhibitor used for the treatment of various solid-organ tumours. It was recently approved as a first- and second-line therapeutic for the management of advanced/metastatic renal cell carcinoma based on the results of two randomised controlled trials. The phase III METEOR trial compared cabozantinib against everolimus as a second- or greater line therapy and found benefits in progression-free and overall survival, and the phase II CABOSUN trial compared cabozantinib against sunitinib as a first-line therapeutic and found benefits in terms of progression-free survival. This review briefly summarises how cabozantinib fits into current treatment paradigms for the management of advanced renal cell carcinoma.https://jkcvhl.com/index.php/jkcvhl/article/view/109cabozantinibfirst-line therapymetastatic renal cell carcinomasecond-line therapy |
| spellingShingle | Sharon Del Vecchio Robert J Ellis Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma Journal of Kidney Cancer and VHL cabozantinib first-line therapy metastatic renal cell carcinoma second-line therapy |
| title | Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma |
| title_full | Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma |
| title_fullStr | Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma |
| title_full_unstemmed | Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma |
| title_short | Cabozantinib for the Management of Metastatic Clear Cell Renal Cell Carcinoma |
| title_sort | cabozantinib for the management of metastatic clear cell renal cell carcinoma |
| topic | cabozantinib first-line therapy metastatic renal cell carcinoma second-line therapy |
| url | https://jkcvhl.com/index.php/jkcvhl/article/view/109 |
| work_keys_str_mv | AT sharondelvecchio cabozantinibforthemanagementofmetastaticclearcellrenalcellcarcinoma AT robertjellis cabozantinibforthemanagementofmetastaticclearcellrenalcellcarcinoma |